DE60042066D1 - Chimärische dr4 antikörper und ihre verwendung - Google Patents

Chimärische dr4 antikörper und ihre verwendung

Info

Publication number
DE60042066D1
DE60042066D1 DE60042066T DE60042066T DE60042066D1 DE 60042066 D1 DE60042066 D1 DE 60042066D1 DE 60042066 T DE60042066 T DE 60042066T DE 60042066 T DE60042066 T DE 60042066T DE 60042066 D1 DE60042066 D1 DE 60042066D1
Authority
DE
Germany
Prior art keywords
antibodies
chimeric
kits
diagnosis
articles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042066T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Anan Chuntharapai
Kelly H Dodge
Kyung Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60042066D1 publication Critical patent/DE60042066D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60042066T 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung Expired - Lifetime DE60042066D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
PCT/US2000/014599 WO2000073349A1 (en) 1999-05-28 2000-05-25 Dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DE60042066D1 true DE60042066D1 (de) 2009-06-04

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042066T Expired - Lifetime DE60042066D1 (de) 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung

Country Status (12)

Country Link
EP (2) EP2213302A3 (de)
JP (1) JP4589586B2 (de)
AT (1) ATE429450T1 (de)
AU (3) AU781952B2 (de)
CA (1) CA2374599A1 (de)
CY (1) CY1109151T1 (de)
DE (1) DE60042066D1 (de)
DK (1) DK1181319T3 (de)
ES (1) ES2325305T3 (de)
IL (1) IL146448A0 (de)
PT (1) PT1181319E (de)
WO (1) WO2000073349A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CN1184315C (zh) 1997-03-17 2005-01-12 人类基因组科学公司 包含死亡结构域的受体－5
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
JP4589586B2 (ja) * 1999-05-28 2010-12-01 ジェネンテック， インコーポレイテッド Ｄｒ４抗体とその利用
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
AU2005271601A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
KR101292961B1 (ko) 2005-02-02 2013-08-02 더 유에이비 리서치 파운데이션 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법
ATE540318T1 (de) 2005-08-16 2012-01-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP2736928B1 (de) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Gegen erbb3-gerichtete sur-bindende proteine
WO2013096828A1 (en) * 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69333082T2 (de) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US6342363B1 (en) * 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
EP1086138B1 (de) * 1998-06-12 2009-09-23 Genentech, Inc. Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
JP4589586B2 (ja) * 1999-05-28 2010-12-01 ジェネンテック， インコーポレイテッド Ｄｒ４抗体とその利用

Also Published As

Publication number Publication date
AU2005201915B2 (en) 2009-01-22
AU781952B2 (en) 2005-06-23
EP1181319B1 (de) 2009-04-22
EP2213302A2 (de) 2010-08-04
AU5296700A (en) 2000-12-18
PT1181319E (pt) 2009-07-14
WO2000073349A1 (en) 2000-12-07
CA2374599A1 (en) 2000-12-07
JP2003503017A (ja) 2003-01-28
IL146448A0 (en) 2002-07-25
AU2005201915A1 (en) 2005-06-02
WO2000073349A9 (en) 2002-05-10
JP4589586B2 (ja) 2010-12-01
ES2325305T3 (es) 2009-09-01
AU2009201670A1 (en) 2009-05-21
DK1181319T3 (da) 2009-08-17
CY1109151T1 (el) 2014-07-02
EP1181319A1 (de) 2002-02-27
ATE429450T1 (de) 2009-05-15
EP2213302A3 (de) 2010-11-03

Similar Documents

Publication Publication Date Title
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NZ513629A (en) C-21 modified epothilones
ATE252578T1 (de) 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
ATE528392T1 (de) Neues protein und dessen dns
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ATE248781T1 (de) Glaspulver und dessen verwendung
DE3767504D1 (de) Tetrahydrobenz(c,d)indol-derivate, ihre salze, verfahren zur herstellung, verwendung als arzneimittel, ihre zusammensetzungen und zwischenprodukte.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition